(Q39394916)

11 September 2017

title

Menopause after breast cancer: a survey on breast cancer survivors (English)

1 reference

11 September 2017

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12753941

3 January 2024

1

Nicoletta Biglia

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12753941

3 January 2024

4

Riccardo Ponzone

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12753941

3 January 2024

6

Furio Maggiorotto

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12753941

3 January 2024

7

Piero Sismondi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12753941

3 January 2024

author name string

Marilena Cozzarella

series ordinal

2

1 reference

11 September 2017

Franca Cacciari

series ordinal

3

1 reference

11 September 2017

Riccardo Roagna

series ordinal

5

1 reference

11 September 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12753941

3 January 2024

publication date

1 May 2003

1 reference

11 September 2017

30 May 2003

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12753941

3 January 2024

number of pages

10

1 reference

full work available at URL

inferred from page(s)

https://api.elsevier.com/content/article/PII:S0378512203000872?httpAccept=text/xml

1 reference

10.1016/S0378-5122(03)00087-2

DOI

https://api.crossref.org/works/10.1016/S0378-5122(03)00087-2

https://api.elsevier.com/content/article/PII:S0378512203000872?httpAccept=text/plain

3 January 2024

1 reference

10.1016/S0378-5122(03)00087-2

DOI

https://api.crossref.org/works/10.1016/S0378-5122(03)00087-2

3 January 2024

1 reference

11 September 2017

volume

45

1 reference

11 September 2017

issue

1

1 reference

11 September 2017

page(s)

29-38

1 reference

Risk of menopause during the first year after breast cancer diagnosis

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2803%2900087-2

7 January 2021

Menopause and breast cancer: symptoms, late effects, and their management

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2803%2900087-2

7 January 2021

Treatment of postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2803%2900087-2

7 January 2021

Controversial issues in climacteric medicine I. Cardiovascular disease and hormone replacement therapy. International Menopause Society Expert Workshop. 13-16 October 2000, royal society of medicine, London, UK.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2803%2900087-2

7 January 2021

Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2803%2900087-2

7 January 2021

Tamoxifen-induced hot flashes

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2803%2900087-2

7 January 2021

Acute menopause symptoms during adjuvant systemic treatment for breast cancer: a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2803%2900087-2

7 January 2021

Circadian rhythm of objectively recorded hot flashes in postmenopausal breast cancer survivors

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2803%2900087-2

7 January 2021

Treatment of estrogen deficiency symptoms in women surviving breast cancer. The Hormone Foundation, Canadian Breast Cancer Research Initiative, National Cancer Institute of Canada, Endocrine Society, and the University of Virginia Cancer Center and

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2803%2900087-2

7 January 2021

Megestrol Acetate for the Prevention of Hot Flashes

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2803%2900087-2

7 January 2021

Long term use of megestrol acetate by cancer survivors for the treatment of hot flashes

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2803%2900087-2

7 January 2021

Hormone replacement therapy as treatment of breast cancer--a phase II study of Org OD 14 (tibilone).

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2803%2900087-2

7 January 2021

Effect of oral gamolenic acid from evening primrose oil on menopausal flushing

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2803%2900087-2

7 January 2021

Prospective evaluation of vitamin E for hot flashes in breast cancer survivors

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2803%2900087-2

7 January 2021

Transdermal clonidine for ameliorating tamoxifen-induced hot flashes

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2803%2900087-2

7 January 2021

Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: A North Central Cancer Treatment Group Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2803%2900087-2

7 January 2021

Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2803%2900087-2

7 January 2021

Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2803%2900087-2

7 January 2021

A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2803%2900087-2

7 January 2021

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2803%2900087-2

7 January 2021

Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2803%2900087-2

7 January 2021

Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2803%2900087-2

7 January 2021

Hormone replacement therapy and breast cancer: a qualitative review

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2803%2900087-2

7 January 2021

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2803%2900087-2

7 January 2021

Estrogen replacement therapy after treatment for localized breast carcinoma. Patient responses and opinions

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2803%2900087-2

7 January 2021

Hormone replacement therapy in women with breast cancer. Do the risks outweigh the benefits?

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2803%2900087-2

7 January 2021

Is hormone replacement therapy safe for breast cancer patients?

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2803%2900087-2

7 January 2021

Estrogen replacement therapy in women with previous breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2803%2900087-2

7 January 2021

A case-control study of hormone replacement therapy after primary surgical breast cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2803%2900087-2

7 January 2021

Hormone replacement therapy after breast cancer: a systematic review and quantitative assessment of risk

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2803%2900087-2

7 January 2021

A cohort study of hormone replacement therapy given to women previously treated for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2803%2900087-2

7 January 2021

Breast cancer survival and hormone replacement therapy: a cohort analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2803%2900087-2

7 January 2021

Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2803%2900087-2

7 January 2021

10.1016/S0378-5122(03)00087-2

Identifiers

DOI

1 reference

11 September 2017

1 reference